Synovial Sarcoma

Here, we describe two patients with EWSR1::PATZ1 sarcoma, of which one patient was initially misdiagnosed as synovial sarcoma and RMS on two occasions. These patients underscore the diagnostic challenges and therapeutic uncertainties surrounding EWSR1::PATZ1 fusion sarcomas, emphasizing the need for further large collaborative studies to establish optimal prognostic implications and management strategies for this rare entity.

P2/3, N=140, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

This case highlights that synovial sarcoma can exhibit a myxoid phenotype and may lack epithelial marker expression, both of which can complicate the diagnosis. It also underscores the importance of integrating molecular analyses, particularly fusion-oriented genomic testing, for accurate diagnosis in challenging soft-tissue tumors.

Here, we demonstrate no cross reactivity in various carcinomas. These results further support that the SS18::SSX fusion specific antibody is highly specific for synovial sarcoma.

Postoperatively, the patient received chemotherapy with epirubicin combined with ifosfamide. Follow-up showed no significant evidence of metastasis or recurrence. This report aims to provide clinical reference regarding the imaging findings and diagnosis of this rare disease, primary renal synovial sarcoma.

These CAR-T cells showed effector responses and antitumor effects against synovial sarcoma cells in vitro, as demonstrated by the results of the intracellular cytokine production, cytokine secretion, CD107a degranulation assay, WST-8 assay, and real-time cell analysis, and in vivo in an NSG mouse xenograft model of synovial sarcoma. Although further mechanistic, translational, and safety validation studies are required, these findings provide a preliminary disease-specific preclinical proof of concept for HLA-independent NKG2D-based CAR-T cell therapy in synovial sarcoma, particularly in patients who are ineligible for or have not responded to TCR-T therapy.

In vivo, apatinib markedly suppressed xenograft tumor growth and modulated the corresponding signaling pathways. Collectively, our findings identify apatinib as a promising therapeutic agent that disrupts interconnected survival and angiogenic networks in SS.

P1, N=9, Recruiting, Zelluna Immunotherapy AS

In conclusion, miR-29b-5p may suppresses cancer stemness and aggressiveness in SS to some extent by targeting EP300, with a relatively more pronounced effect in SSX1 cells. Preliminarily these fundings suggest that miR-29b-5p-mediated modulation of EP300 and the TGF-β signaling pathway may provide a potential research data for synovial sarcoma studies.

Synchronous presentation of differentiated thyroid carcinoma and other malignancies in pediatric patients, while rare, poses significant diagnostic and therapeutic challenges. These cases warrant multidisciplinary evaluation and may reflect underlying cancer predisposition, immune dysregulation, or previously unrecognized risk factors.

P1, N=30, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026

Meanwhile, despite recent advances in diagnosis and therapy, SS remains a diagnostic and clinical challenge due to the associated broad anatomical distribution and diverse histological patterns. This review aims to provide a comprehensive update on the clinical, molecular, and pathological features of SS, with emphasis on diagnostic strategies and treatment approaches.